Sign up to save your podcasts
Or
Share ASH 2025: CEO Will West describes how CellCentric is seeing results for its oral p300/CBP inhibitor, Inobrodib, in heavily refractory multiple myeloma patients
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
ASH 2025: CEO Will West describes how CellCentric is seeing results for its oral p300/CBP inhibitor, Inobrodib, in heavily refractory multiple myeloma patients
Shares an update on the company's ASH data, and also on plans to move into earlier lines of treatment. A registrational study is already set to begin in early 2026.
View all episodes
By BiotechTV
4.3
77 ratings
Shares an update on the company's ASH data, and also on plans to move into earlier lines of treatment. A registrational study is already set to begin in early 2026.
More shows like BiotechTV - News
View all
WSJ What’s News
4,321 Listeners
The a16z Show
1,095 Listeners
The Meb Faber Show - Better Investing
949 Listeners
The Daily
111,767 Listeners
The Readout Loud
336 Listeners
The Intelligence from The Economist
2,540 Listeners
The Prof G Pod with Scott Galloway
5,363 Listeners
All-In with Chamath, Jason, Sacks & Friedberg
10,102 Listeners
Business Of Biotech
86 Listeners
BioCentury This Week
34 Listeners
Biotech Hangout
21 Listeners
BG2Pod with Brad Gerstner and Bill Gurley
477 Listeners
Prof G Markets
1,438 Listeners
The BioCentury Show
11 Listeners
The Studio at Kendall Square
0 Listeners
Off-Target Effects with Matt Gline
4 Listeners
Biotech CEO Sisterhood
3 Listeners
BioVenture VoiCes with Chris Garabedian
6 Listeners